-
Insilico Biomolecular Knowledge Discovery
-
Technology PlatformWe are building a TechBio knowledge discovery & predictions platform to structure biomolecule information, accelerate discoveries and reduce failures in Life Science R&D. The in silico discovery platform combines natural language processing for biomedical literature, machine learning for identifying signals in genomics and clinical trials data, and AI classification of experiment images. We are building our capabilities via partnerships to combine in silico predictions with in vitro data generated specifically for BioXplor's AI workflow.
-
BioXplor has built a unique biomedical knowledge-base consisting of billions of data points from biomedical literature, images, bioinformatics databases and clinical trials.The structured knowledgebase consists of 35 million biomedical documents, 7 million images, 500 thousand clinical trials, 250 bioinformatics databases and 50 biomedical ontologies, and we integrate our pharma and biotech client's data into our system and models for combined analysis and interpretation.Biomedical Knowledgebase
BioXplor has access to proprietary patient genomics and medical databases via partnerships and inhouse data collection programs. We are planning to generate our own cell-based disease models to generate data specifically for our AI models.
-
About us
BioXplor was founded in January 2017 and is a UC Berkeley Skydeck and Merck accelerator company. Pavels Kartasevs, MEng (Computer Engineering), MSc (Bioinformatics) is CTO, and has a rare combined background in high performance computing, bioinformatics and software engineering, having worked in research at Cranfield University and previously led technology at another startup in London, prior to BioXplor. Anna O'Leary, BA (Economics & Finance) is COO, and has started businesses herself as well as having won management awards for change management and team building, and she also established the first student partnership between University of Limerick and UBS Global Markets in the US. Mark has a commercial background in emerging biotechnology and gene-editing and a research background in adult stem cell-based gene therapy, protein-protein interaction screening, and mES transgenic model development. He was previously Associate Director, Emerging Biotechnology Initiative at Merck KgaA, where he ran their first grant program targeting high potential biotech startups in Europe.
BioXplor has formed a multi-disciplinary team of over 20 academic and industry expert advisors, employees, and consultants to enable cutting-edge technology development and data-driven biomedical discoveries. The team is based in the USA and Europe, and uniquely combines expertise in software and data engineering, high-performance computing, machine learning, natural language processing, biomedical science, clinical trials, & drug discovery.
Contact
Partners
